RxDoctor Payments Data

Derek Patel, MD

Gastroenterology · San Diego, CANPI 1073538385

Payments from drug & device makers

$41,714in general payments, 2019–2025

Across 85 payments — averaging $490.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$41K
  • Janssen Scientific Affairs, LLC$125
  • Takeda Pharmaceuticals U.S.A., Inc.$29
  • Pfizer$27
  • Aimmune Therapeutics, Inc.$19
  • Boston Scientific$14
  • plus $23 from 2 others

What the payments were for

  • Speaking & faculty fees$34,65083%
  • Travel & lodging$5,77814%
  • Food & beverage$1,2753%
  • Education$120%

General payments by program year

19
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$41,714 in reported general payments places this provider in the 85th percentile of 1,885 gastroenterology providers in California.

See all gastroenterology providers in California

Medicare billing

Part B allowed, 2024
$92,134
Medicare patients
388
Services billed
685

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab45$1,171,033
RinvoqUpadacitinib49$310,034
Skyrizi On-BodyRisankizumab-Rzaa11$210,177
Humira(Cf) PenAdalimumab13$169,035
LinzessLinaclotide53$40,041
XifaxanRifaximin12$27,528
MotegrityPrucalopride Succinate33$24,783
Mesalamine15$9,681
TrulancePlecanatide13$7,572
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates62$4,011
Sucralfate19$1,869
Omeprazole104$995
Dicyclomine Hcl29$726
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg32$696
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl40$571

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$11$1,171,03345 claims
AbbVieRinvoq, Linzess$41,478$350,075102 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$29$24,78333 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,885 gastroenterology providers in California.

Other gastroenterology in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →